Skip to main content

MoneyWorks4Me

Marksans Pharma informs about press release

15 May 2025 Evaluate

Marksans Pharma has informed that (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1905.00
Dr. Reddys Labs. 1385.00
Cipla 1406.00
Lupin 2012.00
Zydus Lifesciences 1213.05
View more..